<DOC>
	<DOCNO>NCT02745678</DOCNO>
	<brief_summary>The purpose study investigate novel thermosensitive topical gel formulation treatment inflammatory bowel disease ( IBD ) , specifically ulcerative colitis .</brief_summary>
	<brief_title>Localized Therapeutics Treatment Gastrointestinal Disorders II</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>Voluntarily sign write informed consent . Male nonpregnant nonlactating female least 8 year age . Confirmed diagnosis active , mild moderate ulcerative proctitis proctosigmoiditis extend 40cm anal verge . Typically , baseline Mayo Disease Activity Index ( MMDAI ) score 5 10 ( indicate mild moderate disease ) . Known infection Clostridium difficile ( C. difficile ) and/or enteric pathogens 5aminosalicylic acid ( 5ASA ) intolerance Current recent ( 3 week ) oral rectal steroid History thiopurine Antitumor necrosis factor ( AntiTNF ) alpha treatment colitis Abnormal creatinine Previous small bowel colonic resection , Anal sphincter incompetence , Current smoker . History current diagnosis Crohn 's disease indeterminate colitis . History diverticulitis , collagenous colitis , celiac disease , recurrent pancreatic know gallbladder disease . Unstable significant cardiovascular , endocrine , neurologic pulmonary disease . Hemoglobin level &lt; 7.5 g/dL . History sclerosing cholangitis , cirrhosis , hepatic impairment Pregnant risk pregnancy . Some medication treat UC prohibit participation study , include laxative antidiarrhea medication ; oral 5ASA agent daily fiber supplement allow .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Enema</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>